Continuum Advisory’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Continuum Advisory's PTGX Position: Q3 2026 in Review
Continuum Advisory opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 27 shares worth $3.8K. The stake represents ﹤0.01% of the portfolio and ranks #1516 among its holdings.
380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Continuum Advisory held 27 shares of Protagonist Therapeutics worth $3.8K as of Q3 2026.
- Protagonist Therapeutics was a new Continuum Advisory position in Q3 2026.
- Protagonist Therapeutics made up ﹤0.01% of Continuum Advisory's portfolio in Q3 2026, its #1516 holding.
- 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Continuum Advisory's 13F filing for Q3 2026, filed 13 Nov 2026.